Roche stalls; Genentech soldiers on

A Genentech official tells the WSJ Health Blog that the company's morale hasn't been affected by the still-treading-water Roche buyout. Nor have employees begun to head for the doors. But In the Pipeline is skeptical, both of the supposed unchanged morale and of the eventual deal itself. Report | Report

Suggested Articles

Mobile has become universal, accessible, and multi-generational. It’s time for life science brands to revolutionize how they’re telling their story.

Former Retrophin CEO was hoping for a SCOTUS hail mary to escape his seven-year fraud sentences Turns out the court was interest in hearing his plea.

A new investigation shines light on how Purdue pushed back on negative coverage of opioids, placed opioid-friendly experts in think tanks and more.